A study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD6234 after repeat dose administration in participants who are overweight or obese

Trial Identifier: D8750C00002
Sponsor: AstraZeneca
Collaborator:
Parexel
NCTID:: NCT06132841
Start Date: November 2023
Primary Completion Date: April 2025
Study Completion Date: April 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
DE Berlin, DE, 14050
GB Harrow, GB, HA1 3UJ
US, MD Brooklyn, MD, US, 21225